



MAST Study

Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant


OVERVIEW

Gut bacteria play a key role in immune support and recovery. However, treatments like antibiotics and chemotherapy disrupt this balance, increasing infection risks and complications from a stem cell transplant.

We are exploring a ground breaking therapy, IMT (Intestinal Microbiota Transplant), to restore gut health and improve outcomes after stem cell transplants (also known as bone marrow transplants).


We aim to reset your gut microbes, reduce infections, and enhance patient recovery after transplants.

The treatment




A single dose of oral capsules containing healthy donor bacteria. The capsules have no smell or taste.

Trial design




50 participants will be randomized (1:1) to receive either IMT capsules or a placebo before their transplant.

Expected benefit



Early studies showed IMT reduces infections, and supports better recovery. This trial will evaluate its broader impact on patient health and transplant outcomes.

Safety



Previous studies have shown IMT to be safe and well-tolerated. This treatment has been administered to thousands of patients worldwide. Only healthy, rigorously screened donors are used.

**JOIN THE MAST STUDY TO
ADVANCE RESEARCH TOWARDS
IMPROVING OUTCOMES FOR STEM
CELL TRANSPLANT PATIENTS.**

CONTACT

✉ mast-trial@imperial.ac.uk

Scan to see our
website for more info!

